Abstract
Xanthomas are observed in disorders of lipid and lipoprotein metabolism, as well as lymphoproliferative malignancies. Xanthomas can signalize an increased risk for dyslipidemia or disorders of lipid metabolism associated with serious metabolic and cardiovascular diseases, in addition to paraproteinemia and lymphoproliferative disorders. Some types of xanthoma are pathognomonic for special lipid disorders. The most prevalent xanthoma is xanthelasma palpebrarum, which, in association with tuberous and tendinous xanthomas, is typical for autosomal-dominant familial hypercholesterolemia, as along with some rare disorders of sterol metabolism, such as β-sitosterolemia and cerebrotendinous xanthomatosis. Eruptive xanthomas point to severe hypertriglyceridemia, decompensated type 2 diabetes mellitus, and increased risk for acute pancreatitis. Xanthoma striatum palmare is pathognomonic for primary dysbetalipoproteinemia associated with an elevated risk for early onset of coronary and peripheral vascular disease. Diffuse plane xanthomas are found in association with paraproteinemia and lymphoproliferative disorders. The occurrence of xanthomas should alert the dermatologist to unravel its cause and potential risk constellations. This chapter provides basic information on disorders of lipid metabolism associated with xanthoma formation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Lipoproteins and Lipid Metabolism
Armstrong EJ, Krueger JG (2016) Lipoprotein metabolism and inflammation in patients with psoriasis. Am J Cardiol 118:603–609
Arnao V, Tuttolomondo A, Daidone M, Pinto A (2019) Lipoproteins in atherosclerosis process. Curr Med Chem 26:1525–1543
Ashur-Fabian O, Har-Zahav A, Shaish A et al (2010) apoB and apobec1, two genes key to lipid metabolism, are transcriptionally regulated by p53. Cell Cycle 9:3761–3770
Goldstein JL, Brown MS (2009) The LDL receptor. Arterioscler Thromb Vasc Biol 29:431–438
Miyahara Y, Bessho K, Kondou H et al (2015) Negative feedback loop of cholesterol regulation is impaired in the livers of patients with Alagille syndrome. Clin Chim Acta 440:49–54
Nakajima K, Tokita Y, Tanaka A, Takahashi S (2019) The VLDL receptor plays a key role in the metabolism of postprandial remnant lipoproteins. Clin Chim Acta 495:382–393
Orekhov AN, Sobenin IA (2019) Modified and dysfunctional lipoproteins in atherosclerosis: effectors or biomarkers? Curr Med Chem 26:1512–1524
Orsó E, Schmitz G (2017) Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies. Clin Res Cardiol 12(Suppl 1):31–37
Orsó E, Grandl M, Schmitz G (2011) Oxidized LDL-induced endolysosomal phospholipidosis and enzymatically modified LDL-induced foam cell formation determine specific lipid species modulation in human macrophages. Chem Phys Lipids 164:479–487
Salahuddin T, Natarajan B, Playford MP et al (2015) Cholesterol efflux capacity in humans with psoriasis is inversely related to non-calcified burden of coronary atherosclerosis. Eur Heart J 36:2662–2665
Schaefer EJ, Tsunoda F, Diffenderfer M et al (2016) The measurement of lipids, lipoproteins, apolipoproteins, fatty acids, and sterols, and next generation sequencing for the diagnosis and treatment of lipid disorders. In: De Groot LJ, Beck-Peccoz P, Chrousos G et al (eds) Endotext [Internet]. MDText.com, South Dartmouth
Schmitz G, Grandl M (2008) Lipid homeostasis in macrophages – implications for atherosclerosis. Rev Physiol Biochem Pharmacol 160:93–125
Schmitz G, Langmann S (2006) The lipid flux rheostat: implications of lipid trafficking pathways. J Mol Med 84:262–265
Schmitz G, Brüning T, Williamson E, Nowicka G (1990) The role of HDL in reverse cholesterol transport and its disturbances in Tangier disease and HDL deficiency with xanthomas. Eur Heart J 11(Suppl E):197–211
Sorokin AV, Kotani K, Elnabawi YA et al (2018) Association between oxidation-modified lipoproteins and coronary plaque in psoriasis. Circ Res 123:1244–1254
Takahashi S (2017) Triglyceride rich lipoprotein-LPL-VLDL receptor and Lp(a)-VLDL receptor pathways for macrophage foam cell formation. J Atheroscler Thromb 24:552–559
Verbeek R, Hovingh GK, Boekholdt SM (2015) Non-high-density lipoprotein cholesterol: current status as cardiovascular marker. Curr Opin Lipidol 26:502–510
Xanthelasma and Xanthomas
Al Aboud AM, Al Aboud DM (2019) Xanthelasma palpebrarum. SourceStatPearls [Internet]. StatPearls, Treasure Island, FL
Aljenedil S, Ruel I, Watters K, Genest J (2018) Severe xanthomatosis in heterozygous familial hypercholesterolemia. J Clin Lipidol 12:872–877
Barrett AW, Boyapati RP, Bisase BS et al (2019) Verruciform xanthoma of the oral mucosa: a series of eight typical and three anomalous cases. Int J Surg Pathol 27:492–498
Bergman R (1998) Xanthelasma palpebrarum and risk of atherosclerosis. Int J Dermatol 37:343–345
Cruz PD Jr, East C, Bergstresser PR (1988) Dermal, subcutaneous, and tendon xanthomas: diagnostic markers for specific lipoprotein disorders. J Am Acad Dermatol 19:95–111
Frew JW, Murrell DF, Haber RM (2015) Fifty shades of yellow: a review of the xanthodermatoses. Int J Dermatol 54:1109–1123
Guirado SS, Conejo-Mir JS, Muñoz MA et al (2007) Sitosterol xanthomatosis. J Eur Acad Dermatol Venereol 21:100–103
Matsui S, Maruhashi T, Kihara Y, Higashi Y (2019) Giant multiple xanthomas in familial hypercholesterolaemia. Eur Heart J 40:2813
Nair PA, Singhal R (2017) Xanthelasma palpebrarum – a brief review. Clin Cosmet Investig Dermatol 11:1–5
Nguyen AH, Vaudreuil AM, Huerter CJ (2017) Systematic review of laser therapy in xanthelasma palpebrarum. Int J Dermatol 56:e47–e55
Sabatine MS (2016) Advances in the treatment of dyslipidemia. Cleve Clin J Med 83:181–186
Sabatine MS, Giugliano RP, Wiviott SD et al (2015) Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372:1500–1509
Saleh M, Kamath BM, Chitayat D (2016) Alagille syndrome: clinical perspectives. Appl Clin Genet 9:75–82
Santos MA, Foulke G (2019) Koebnerization and eruptive xanthomas. J Gen Intern Med 34:1947–1948
Stiff KM, Cohen PR (2017) Vegas (verruciform genital-associated) xanthoma: a comprehensive literature review. Dermatol Ther (Heidelb) 7:65–79
Wang H, Shi Y, Guan H et al (2016) Treatment of xanthelasma palpebrarum with intralesional pingyangmycin. Dermatol Surg 42:368–376
Winkler JK, Hoffmann J, Enk A, Toberer F (2019) Diffuse plane xanthomas associated with mycosis fungoides. Hautarzt 70:438–442
Zak A, Zeman M, Slaby A, Vecka M (2014) Xanthomas: clinical and pathophysiological relations. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 158:181–188
Primary and Secondary Dyslipoproteinemia
Andersen LH, Miserez AR, Ahmad Z, Andersen RL (2016) Familial defective apolipoprotein B-100: a review. J Clin Lipidol 10:1297–1302
Arca M, Zuliani G, Wilund K et al (2002) Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in AHR: a clinical and molecular genetic analysis. Lancet 359:841–847
Basani S, Garg A (2015) Marked lowering of high-density lipoprotein cholesterol levels due to high dose bexarotene therapy. J Clin Lipidol 9:832–836
Cabello I, Servitje O, Corbella X et al (2017) Omega-3 fatty acids as adjunctive treatment for bexarotene-induced hypertriglyceridaemia in patients with cutaneous T-cell lymphoma. Clin Exp Dermatol 42:276–281
Cupido AJ, Reeskamp LF, Kastelein JJP (2017) Novel lipid modifying drugs to lower LDL cholesterol. Curr Opin Lipidol 28:367–373
Gabcova-Balaziova D, Stanikova D, Vohnout B et al (2015) Molecular-genetic aspects of familial hypercholesterolemia. Endocr Regul 49:164–181
Hansen TJ, Lucking S, Miller JJ et al (2016) Standardized laboratory monitoring with use of isotretinoin in acne. J Am Acad Dermatol 75:323–328
Hegele RA, Ginsberg HN, Chapman MJ et al (2014) The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2:655–666
Jellinger PS, Handelsman Y, Rosenblit PD et al (2017) American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease – Executive summary complete. Endocr Pract 23:479–497
Joseph L, Robinson JG (2015) Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and the future of lipid lowering therapy. Prog Cardiovasc Dis 58:19–31
Karr S (2017) Epidemiology and management of hyperlipidemia. Am J Manag Care 23(9 Suppl):S139–S148
Lee YH, Scharnitz TP, Muscat J et al (2016) Laboratory monitoring during isotretinoin therapy for acne: a systematic review and meta-analysis. JAMA Dermatol 152:35–44
Melnik BC, Bros U, Plewig G (1987) Evaluation of the atherogenic risk of isotretinoin-induced and etretinate-induced alterations of lipoprotein cholesterol metabolism. J Invest Dermatol 88(3 Suppl):39s–43s
Oliva CP, Pisciotta L, Li Volti G et al (2005) Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler Thromb Vasc Biol 25:411–417
Pajukanta P, Lilja HE, Sinsheimer JS et al (2004) Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet 36:322–324
Peros E, Geroldi G, D'Angelo A et al (2004) Apolipoprotein (a) phenotypes are reliable biomarkers for familial aggregation of coronary heart disease. Int J Mol Med 13:243–247
Reimund M, Larsson M, Kovrov O et al (2015) Evidence for two distinct binding sites for lipoprotein lipase on glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 (GPIHP1). J Biol Chem 290:13919–13934
Ripatti P, Rämö JT, Söderlund S et al (2016) The contribution of GWAS loci in familial dyslipidemias. PLoS Genet 12:e1006078
Salakhutdinov NF, Laev SS (2014) Triglyceride-lowering agents. Bioorg Med Chem 22:3551–3564
Sarkar T, Sarkar S, Patra A (2018) Low-dose isotretinoin therapy and blood lipid abnormality: a case series with sixty patients. J Family Med Prim Care 7:171–174
Schmitz G, Orsó E (2015) Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects. Clin Res Cardiol Suppl 10:21–25
Singh S, Bittner V (2015) Familial hypercholesterolemia – epidemiology, diagnosis, and screening. Curr Atheroscler Rep 17:482
Taghizadeh E, Mardani R, Rostami D et al (2019) Molecular mechanisms, prevalence, and molecular methods for familial combined hyperlipidemia disease: a review. J Cell Biochem 120:8891–8898
Turgeon RD, Barry AR, Pearson GJ (2016) Familial hypercholesterolemia: review of diagnosis, screening, and treatment. Can Fam Physician 62:32–37
Youngblom E, Pariani M, Knowles JW (2014) Familial hypercholesterolemia. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A (eds) SourceGeneReviews® [Internet]. University of Washington, Seattle; 1993–2019. [updated 8 December 2016]
Sterol Storage Disorders
Berge KE, Tian H, Graf GA et al (2000) Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporter. Science 290:1771–1775
Mandia D, Chaussenot A, Besson G et al (2019) Cholic acid as a treatment for cerebrotendinous xanthomatosis in adults. J Neurol 266:2043–2050
Matysik S, Orsó E, Black A et al (2011) Monitoring of 7α-hydroxy-4-cholesten-3-one during therapy of cerebrotendinous xanthomatosis: a case report. Chem Phys Lipids 164:530–534
Raymond GV, Schiffmann R (2019) Cerebrotendinous xanthomatosis: the rare “treatable” disease you never consider. Neurology 92:61–62
Yoo EG (2016) Sitosterolemia: a review and update of pathophysiology, clinical spectrum, diagnosis, and management. Ann Pediatr Endocrinol Metab 21:7–14
Xanthomas and Xanthomatization in Nonlipid Disorders
Cohen YK, Elpern DJ (2015) Diffuse normolipemic plane xanthoma associated with monoclonal gammopathy. Dermatol Pract Concept 5:65–67
Lee WI, Calma A, Drummond C, Cook MC (2019) Xanthoma and paraproteinaemia: a spot diagnosis. BMJ Case Rep 12(2):pii: bcr-2018-227884
Szalat R, Arnulf B, Karlin L et al (2011) Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy. Blood 118:3777–3784
First Describer
Abifadel M, Varret M, Rabes JP et al (2003) Mutations in the PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34:154–156
Alagille D, Odievre M, Gautier M, Dommergues JP (1975) Hepatic ductular hypoplasia associated with characteristic facies, vertebral malformations, retarded physical, mental and sexual development, and cardiac murmur. J Pediatr 86:63–71
Berg K (1963) A new serum type system in man. Acta Pathol Microbiol Scand 59:369–382
Bhattacharyya AK, Connor WE (1973) β-Sitosterolemia and xanthomatosis: a newly described lipid storage disease in two sisters. J Clin Invest 52:9a
Bodzioch M, Orso E, Klucken J et al (1999) The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 22:347–351
Bürger M, Grütz O (1932) Über hepatosplenomegale Lipidose mit xanthomatösen Veränderungen in Haut und Schleimhaut. Arch Dermatol Syph 166:542–547
Fredrickson DS, Altrocchi PH, Avioli LV et al (1961) Tangier disease – combined clinical staff conference at the National Institutes of Health. Ann Intern Med 55:1016–1031
Fredrickson DS, Levy RI, Lees RS (1967) Fat transport in lipoproteins – an integrated approach to mechanism and disorders. N Engl J Med 276:32–44 94–103, 148–156, 215–226, 273–281
Garcia CK, Wilund K, Arca M et al (2001) Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 292:1394–1398
Gofman JW, DeLalla O, Glazier F et al (1954) The serum lipoprotein transport system in health, metabolic disorders, atherosclerosis and coronary heart disease. Plasma 2:413–428
Goldstein JL, Brown MS (1973) Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity with overproduction of cholesterol. Proc Natl Acad Sci U S A 20:2804–2806
Goldstein JL, Scrap HG, Hazzard WR et al (1973) Hyperlipidemia in coronary artery disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 52:1533–1568
Haddad L, Day IN, Hunt S et al (1999) Evidence for a third genetic locus causing familial hypercholesterolemia: a non-LDLR, non-APOB kindred. J Lipid Res 40:1113–1122
Havel R, Gordon RS (1960) Idiopathic hyperlipidemia: metabolic studies in an affected family. J Clin Invest 39:1777–1782
Innerarity TL, Weisgraber KH, Arnold KS et al (1987) Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci U S A 84:6919–6923
Khachadurian AK, Uthman M (1973) Experiences with the homozygous cases of familial hypercholesterolemia. A report of 52 cases. Nutr Metab 15:132–140
Mahley RW, Angelin B (1984) Type III hyperlipoproteinemia: recent insights into the genetic defect of familial dysbetalipoproteinemia. Adv Intern Med 29:385–411
Müller C (1938) Xanthomata, hypercholesterinemia, angina pectoris. Acta Medica Scand Suppl 89:75–80
Soria LF, Ludwig EH, Clarke HR et al (1989) Association between a specific apolipoprotein B mutation and familial defective apo B-100. Proc Natl Acad Sci U S A 86:587–591
Tada H, Kawashiri MA, Ohtani R et al (2011) A novel type of familial hypercholesterolemia: double heterozygous mutations in LDL receptor and LDL receptor adaptor protein 1 gene. Atherosclerosis 219:663–666
Thannhauser SJ, Magendantz H (1938) The different clinical groups of xanthomatous diseases: a clinical physiological study of 22 cases. Ann Intern Med 11:1662–1746
Utermann G, Jaeschke M, Menzel J (1975) Familial hyperlipoproteinemia type III: deficiency of a specific apolipoprotein (apo E-III) in the very-low-density lipoproteins. FEBS Lett 56:352–355
Van Bogaert L, Scherer HJ, Epstein E (1937) Une forme cérébrale de la cholestérinose géneralisée. Masson, Paris
Vega GL, Grundy SM (1986) In vitro evidence for reduced binding of low density lipoproteins to receptors as a cause of primary hypercholesterolemia. J Clin Invest 78:1410–1415
Watson GH, Miller V (1973) Arteriohepatic dysplasia: familial pulmonary arterial stenosis with neonatal liver disease. Arch Dis Child 48:459–466
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2022 Springer-Verlag GmbH Germany, part of Springer Nature
About this entry
Cite this entry
Melnik, B. (2022). Disorders of Lipid Metabolism. In: Plewig, G., French, L., Ruzicka, T., Kaufmann, R., Hertl, M. (eds) Braun-Falco´s Dermatology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-63709-8_89
Download citation
DOI: https://doi.org/10.1007/978-3-662-63709-8_89
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-63708-1
Online ISBN: 978-3-662-63709-8
eBook Packages: MedicineReference Module Medicine